- Rating
- 3(+1)
- Confidence
- 2
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
The paper presents EviBoltz, a cryo-EM density-conditioned extension of Boltz-2 for experimental atomic model building. Global density features are incorporated into the single and pair representations inside the Pairformer, while local density features are repeatedly queried around current atomic coordinates during diffusion. The model is jointly fine-tuned on paired experimental maps and structures.
The evaluation covers protein–protein, protein–ligand, protein–peptide, and antibody–antigen systems. The paper reports improvements in interface recovery, ligand placement, and local loop geometry, together with a supervised two-state URAT1 experiment examining whether map-conditioned representations can convey conformational-state information to a frozen generator. The relevant application is the interpretation of experimental density maps into atomic models, with the target map providing substantial sample-specific structural information.
Critical strengths
Combining molecular priors with cryo-EM observations is useful for recovering the structure present in a particular experimental sample. Incorporating density into both relational representations and coordinate generation is a reasonable design, and the proposed layer-wise Pairformer conditioning is a potentially useful extension of existing density-conditioned approaches.
Acceptable PPI interface recovery increases from 15/54 to 38/54 cases, and joint protein–ligand success increases from 3/43 to 15/43. The paired source-level analysis and the independently aligned loop-shape evaluation provide additional evidence that the gains extend beyond a few qualitative examples or global rigid-body placement.
Critical weaknesses
The target density is a legitimate input for experimental model building, but it supplies substantial structural information unavailable to density-free Boltz-2. Improvements over Boltz-2 therefore do not, by themselves, isolate the contribution of the proposed architecture. The paper does include density-aware baselines, which is appreciated. However, the adapted implementations, incomplete original runs, and backbone differences make these comparisons difficult to interpret. CryoACE already includes density–sequence fusion, atom-centered density profiling, and eventual end-to-end fine-tuning. The most informative control would therefore compare layer-wise Pairformer conditioning with a simpler density-fusion alternative using the same backbone, training data, and optimization budget. It should also be clarified whether the pathway ablations were independently trained or disabled only at inference.
The reported reference-based accuracy gains are encouraging, but complete output coverage does not establish that all generated regions are supported by the experimental data. In weak-density regions, a generative model may produce plausible coordinates without resolving the underlying ambiguity. A compact evaluation of local map agreement, protein/ligand geometric validity, and accuracy stratified by local density quality would help establish the practical value of the additional coverage. The scope of the task-level claims also needs clearer qualification: the 75% peptide success appears to represent only 3/4 evaluable interfaces from a cohort of 13 cases. Explicit eligibility criteria, counts, and uncertainty are needed to assess how broadly the reported improvements apply.
Questions for authors
-
Were the pathway ablations independently trained under matched settings, or obtained by disabling components only at inference? Is there a matched-backbone and matched-data comparison between layer-wise Pairformer conditioning and post-Pairformer density fusion?
-
What changes were made to the reproduced CryoBoltz and CryoACE pipelines? Please specify the checkpoints, initialization/alignment procedures, sampling budgets, and post-processing, and explain how reproduction fidelity was checked. Were reference coordinates used in any test-time preprocessing or prediction-selection step? A paired comparison on a common completed subset would be helpful.
-
What evidence shows that the increased completeness corresponds to accurate, experimentally supported atoms, particularly in weak-density regions? Please report or point to available local map-agreement and geometric-validity analyses. A large prospective deployment study would be useful future work, but is not necessary to address this question.
-
Please confirm the effective sample counts and explain why only four of the thirteen peptide cases appear to enter interface evaluation. Also, what explains the Boltz-2 ligand RMSD difference between Tables 1 and 2, namely 10.6177 Å versus 11.721 Å?
A Brief Follow-Up on Our Rebuttal
Thank you again for your thoughtful review. As the discussion deadline approaches, we wanted to briefly follow up on our rebuttal. If you have a chance to review our response, we would appreciate hearing whether the additional experiments and clarifications address your main concerns. We would be happy to clarify any remaining points.